Instil Bio’s stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials – MarketWatch

Posted: November 6, 2022 at 2:13 am

Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials  MarketWatch

Read more:
Instil Bio's stock falls 35% after disclosing the cell therapy company paused enrollment in clinical trials - MarketWatch

Related Post